Arena Pharmaceuticals vs. Vivus: Which Is a Better Weight Loss Drug for Investors?

Arena Pharmaceuticals (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) are battling in the minds of investors as each promises a drug with the potential to cause weight loss- a sure moneymaker in a country in which many people are unhappy with their weight. Vivus’s drug, Qsymia (also known as Qnexa), was approved by the FDA earlier this month. Arena’s Belviq has also been approved, though it should come to market later than Qsymia if both drugs are released on schedule. At a basic level, the contest between the two drugs is between efficiency and safety concerns, while the contest between the two companies involves the marketability of their drugs and their ability to profit.

While Qsymia is somewhat more effective than Belviq, according to study data, the gap is not particularly large: Belviq trial subjects lost 3-4% of their body weight in one year, and some subjects saw much larger losses, compared to Qsymia’s average of 10% of body weight lost in the highest tested dose. In addition, one of Qsymia’s active ingredients has been shown to increase the risk of birth defects; again, the safety gap might not be particularly large in Belviq’s favor, with Arena attempting to rule out potential cancer and heart health risks from the drug. However, given these differences, even if patients might tend to prefer Qsymia physicians might encourage them to take Belviq, at least at first. Doctors might also spin the information provided in order to encourage their patients to go with Arena’s drug and therefore reduce the risk of complications and expensive legal disputes.

John Burbank PASSPORT CAPITAL

Clearly the strengths and weaknesses of the two drugs convert to advantages and disadvantages of each company relative to the other, but each has an additional drawback. Arena has an agreement to only receive a minority of the revenue from Belviq sales in the US, with the remainder going to a partner who will market the drug and also cover much of the costs of additional clinical trials; Vivus has no such agreement. Vivus’s problem is less certain, but potentially more damaging. Citron Research, a group which publishes investigations of stocks which it believes have had their prospects tremendously overvalued by the Street, turned its sights on the company earlier this month. The stock has fallen about 13% since Citron claimed that one of the compounds used in Qsymia is under patent protection for weight loss treatment and that the drug is a combination of two widely available generics, among other accusations. Unless investors have the legal background to analyze and reject these claims, or are willing to take substantial financial risk, they may want to avoid the stock. Citron and many critics of Vivus also discuss insider selling activity at the company (see a history of insider selling at Vivus).

Between the two, hedge funds have generally bet on Vivus despite the dispute over the companies’ product offerings. According to 13F filings, Daniel Gold’s QVT Financial owned 8.2 million shares of VVUS at the end of March 2012. This made it the largest holding in his 13F portfolio, and made QVT the largest hedge fund holder of the stock. QVT is also the largest hedge fund holder of ARNA, according to the same filings, but only owned 3.3 million shares; taking the two stocks’ prices into account, QVT’s position in VVUS was 18 times larger (see the rest of QVT’s portfolio). Passport Capital, managed by John Burbank, increased its holdings of VVUS in the first three months of 2012 to 7.4 million shares (find other stock picks from Passport Capital).

We think that the intellectual property issues and insider selling at Vivus are causes for concern, and our guess is that, barring any unforeseen developments, doctors will tend to recommend the somewhat safer Belviq to their patients, with Qsymia being a “plan B” in the event the first drug is not effective enough. This is particularly true for patients who are seeking to lose weight for cosmetic rather than purely medical reasons, a large segment of the market for a weight loss drug.  While Arena would not fully benefit from Belviq’s market opportunity, the stock may be a better buy than Vivus.

This article was updated to include information about Arena’s marketing agreement for Belviq.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!